Canadian researcher Gerry Wright is searching for the next generation of life-saving antibiotics

Wright Lab has published three novel antimicrobials this year — including lariocidin (Nature) — and has two additional candidates under peer review, one representing a novel antibiotic class. Commercialization risk is high: antibiotic development typically requires ~10+ years and >US$1 billion, the antibiotics market is described as "broken," and industry investors/grants have so far been unavailable. Scientific upside is significant given AMR projections (up to 10 million deaths annually by 2050) but near-term investability and revenue prospects remain constrained.

Analysis

Academic breakthroughs in natural‑product discovery are shifting the value pool away from the discovery stage and toward translational bottlenecks: IP aggregation, GLP/tox de‑risking, and scale fermentation/CMC. That reallocates durable cashflows to service providers (specialized CDMOs/CROs) and to financiers who can buy or underwrite early IP and shepherd it through IND‑enabling work, rather than to pure discovery shorts.

The single largest tail risk is biological: an otherwise promising scaffold can fail on toxicity or rapidly select resistance once exposed at scale — outcomes that will destroy equity in early‑stage owners but leave contracted service providers relatively insulated. Policy catalysts (subscription/pull payments, targeted government grants or advance‑purchase commitments) are the primary macro levers that meaningfully re‑rate antibiotic economics; these are binary and typically emerge on 6–24 month political timelines.

Markets are currently mispricing where value accrues. Public small‑caps that own early chemistry are priced as if they will single‑handedly commercialize, yet the more robust, lower‑beta way to harvest this wave is via: (a) selective venture/royalty exposure to validated academic assets, and (b) leveraged exposure to CRO/CDMO chains and diagnostics that capture steady fee revenue as the sector scales. That construct offers asymmetric upside while limiting catastrophic downside from clinical failures.

Key Decisions for Investors

• Initiate a $25–50m cornerstone venture/royalty commitment to a Canadian antibiotic spinout (priority: tech‑transfer from McMaster). Timeframe: deploy over 6–18 months with staged tranche funding tied to IND‑enabling milestones. R/R: 5x+ on successful Phase 1/2 licences; downside: total loss of capital if preclinical fails — mitigated by royalty structure.
• Buy Thermo Fisher (TMO) — 6–12 month horizon. Rationale: captures incremental reagent, sequencing and diagnostic demand as AMR programs expand; entry: buy 1–2% NAV position or buy 6–12 month calls to leverage. Risk: high valuation; downside 10–20% if macro slows; upside 15–30% if public AMR funding ramps.
• Buy Catalent (CTLT) and/or ICON (ICLR) pair — 3–9 month horizon. Trade: long CTLT (or CTLT 6–9 month calls) / long ICLR to capture increase in CMC and clinical services demand. R/R: moderate (20–40% upside) with limited binary risk versus equity ownership of drug assets.
• Pair trade: short a small‑cap pure‑play antibiotic developer (example: PRTK) versus long CTLT — 9–18 month horizon. Thesis: high failure probability for asset owners; service providers win regardless of which molecules fail. Risk: single‑asset clinical success in the short term could invert losses; keep position sizes limited and use options to cap downside.